Download the poster explaining how Trailblazer, the versatile antibody assembly platform, allows you to rapidly switch antibody formats to identify and build the antibody you need, in the best format for your assay.
Learn more: ow.ly/82Rh50RYz4N#Antibodies
Discover antibodies recognizing the #MMAE toxin, which can be linked to monoclonal antibodies to form an antibody-drug conjugate. Upon binding to the target, the toxin is released in the cell, activating an antimitotic mechanism.
Learn more: ow.ly/zgkv50RSgz9#Biopharma
Is it time to investigate if the power of AI and machine learning could streamline data analysis in your lab? Join our webinar to find out more about the benefits of computational cytometry for drug discovery.
Register now: ow.ly/qNGA50RYG4q#DrugDiscovery#FlowCytometry
Download the new poster to learn how the Trailblazer Platform uses SpyTag technology for the fast and simple site-specific attachment of labels to recombinant antibodies.
Download now: ow.ly/WpXj50RYy0Z#Antibodies#Biotherapeutics#DrugDiscovery
This blog focuses on recent research investigating how cats produce purring vocalizations, bringing us one step closer to better understanding our mysterious little furry companions!
Read the blog to find out more: ow.ly/CKkJ50RSR0L#LabCrunches#Cats#Purring
Bio-Rad's type 1 anti-avelumab antibodies inhibit the binding of the drug avelumab to its target, PD-L1, while the type 3 antibodies specifically recognize the drug-target complex, detecting avelumab only when bound to PD-L1.
Find out more: ow.ly/OR9150RSQV6#Biopharma
The MMAE toxin is a very potent antimitotic agent used as a payload for developing antibody-drug conjugates blocking cell division. They are ideal for the development of PK bridging ELISAs to measure antibody drugs conjugated to those toxins.
Learn more: ow.ly/zZR350RSQWt
Develop highly selective and sensitive PK and ADA assays for the antibody drug avelumab (Bavencio) using our new range of ready-made anti-idiotypic antibodies.
Learn more: ow.ly/1hpB50RHZ7a#Biotherapeutics#Biopharma#DrugDiscovery
The development of biosimilars is hoped to reduce the costs of biotherapeutics, making them more accessible to those in need. Read the article to find out how biosimilars could increase treatment options for patients with lung cancer.
Learn more: ow.ly/Qabo50RIa99
Have you ever wondered how your cat is able to produce that familiar rumbling purring noise? In this blog, we discuss a recent paper in which they shine a new light on the mechanisms that drive purring in cats.
Read more: ow.ly/Lbps50RIPuY#LabCrunches#Cats#Purring
Immune checkpoint therapy has revolutionized cancer treatment, yet over 50 percent of patients fail to respond to immunotherapy. Could the gut microbiota of the patient influence immunotherapy outcomes? Read the blog to find out: ow.ly/trqY50RA6lC#LabCrunches#Microbiota